➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Boehringer Ingelheim
Moodys
AstraZeneca

Last Updated: June 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for SHR3162


Email this page to a colleague

« Back to Dashboard

What is the drug development status for SHR3162?

SHR3162 is an investigational drug.

There have been 17 clinical trials for SHR3162. The most recent clinical trial was a Phase 1 trial, which was initiated on March 31st 2021.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Ovarian Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Atridia Pty Ltd.

There are two US patents protecting this investigational drug and twenty-one international patents.

Recent Clinical Trials for SHR3162
TitleSponsorPhase
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine Co., Ltd.Phase 2
A Phase III Study of Fluzoparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Jiangsu HengRui Medicine Co., Ltd.Phase 3
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian CancerJiangsu HengRui Medicine Co., Ltd.Phase 1

See all SHR3162 clinical trials

Clinical Trial Summary for SHR3162

Top disease conditions for SHR3162
Top clinical trial sponsors for SHR3162

See all SHR3162 clinical trials

US Patents for SHR3162

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SHR3162   Try Before You Buy Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)   Try Before You Buy
SHR3162   Try Before You Buy Methods of using phthalazinone ketone derivatives Jiangsu Hansoh Pharmaceutical Co., Ltd. (Lianyungang, Jiangsu, CN)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SHR3162

Drugname Country Document Number Estimated Expiration Related US Patent
SHR3162 Australia AU2011288876 2030-08-09   Try Before You Buy
SHR3162 Brazil BR112013002220 2030-08-09   Try Before You Buy
SHR3162 Canada CA2806324 2030-08-09   Try Before You Buy
SHR3162 China CN102372716 2030-08-09   Try Before You Buy
SHR3162 China CN102686591 2030-08-09   Try Before You Buy
SHR3162 European Patent Office EP2604610 2030-08-09   Try Before You Buy
SHR3162 Spain ES2582315 2030-08-09   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
Johnson and Johnson
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.